The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
Volume 345:1719-1726 December 13, 2001 Number 24
NextNext

The Effect of Group Psychosocial Support on Survival in Metastatic Breast Cancer
Pamela J. Goodwin, M.D., Molyn Leszcz, M.D., Marguerite Ennis, Ph.D., Jan Koopmans, M.S.W., Leslie Vincent, R.N., Helaine Guther, M.S.W., Elaine Drysdale, M.D., Marilyn Hundleby, Ph.D., Harvey M. Chochinov, M.D., Ph.D., Margaret Navarro, M.D., Michael Speca, Psy.D., Julia Masterson, M.D., Liz Dohan, M.S.W., Rami Sela, Ph.D., Barbara Warren, R.N., M.S.N., Alexander Paterson, M.D., Kathleen I. Pritchard, M.D., Andrew Arnold, M.B., B.S., Richard Doll, M.S.W., Susan E. O'Reilly, M.D., Gail Quirt, R.N., B.A.A., Nicky Hood, R.N., and Jonathan Hunter, M.D.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Commentary
-Editorial
 by Spiegel, D.

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background Supportive–expressive group therapy has been reported to prolong survival among women with metastatic breast cancer. However, in recent studies, various psychosocial interventions have not prolonged survival.

Methods In a multicenter trial, we randomly assigned 235 women with metastatic breast cancer who were expected to survive at least three months in a 2:1 ratio to an intervention group that participated in weekly supportive–expressive group therapy (158 women) or to a control group that received no such intervention (77 women). All the women received educational materials and any medical or psychosocial care that was deemed necessary. The primary outcome was survival; psychosocial function was assessed by self-reported questionnaires.

Results Women assigned to supportive–expressive therapy had greater improvement in psychological symptoms and reported less pain (P=0.04) than women in the control group. A significant interaction of treatment-group assignment with base-line psychological score was found (P<=0.003 for the comparison of mood variables; P=0.04 for the comparison of pain); women who were more distressed benefited, whereas those who were less distressed did not. The psychological intervention did not prolong survival (median survival, 17.9 months in the intervention group and 17.6 months in the control group; hazard ratio for death according to the univariate analysis, 1.06 [95 percent confidence interval, 0.78 to 1.45]; hazard ratio according to the multivariate analysis, 1.23 [95 percent confidence interval, 0.88 to 1.72]).

Conclusions Supportive–expressive group therapy does not prolong survival in women with metastatic breast cancer. It improves mood and the perception of pain, particularly in women who are initially more distressed.


Source Information

From the Departments of Medicine (P.J.G.), Psychiatry (M.L., J.H.), and Nursing (L.V.), and the Division of Clinical Epidemiology at the Samuel Lunenfeld Research Institute (P.J.G., M.E.), Mount Sinai Hospital, University of Toronto, Toronto; the Department of Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, Alta. (J.K., M.S.); the Department of Supportive Care, Hamilton Regional Cancer Center, Hamilton, Ont. (H.G.); the Department of Psychiatry, University of British Columbia, Vancouver, and the British Columbia Cancer Agency, Vancouver (E.D.); the Department of Psychology, University of Alberta, Edmonton, and the Cross Cancer Institute, Edmonton, Alta. (M.H.); the Department of Psychiatry, University of Manitoba, Winnipeg, and CancerCare Manitoba, Winnipeg (H.M.C.); and the Department of Psychiatry, University of Ottawa, and the Ottawa Regional Cancer Center, Ottawa, Ont. (M.N.) — all in Canada.

Other authors were Julia Masterson, M.D., Department of Supportive Care, Hamilton Regional Cancer Center, Hamilton, Ont.; Liz Dohan, M.S.W., Department of Patient and Family Counseling, British Columbia Cancer Agency, Vancouver; Rami Sela, Ph.D., Department of Psychology, University of Alberta, Edmonton; Barbara Warren, R.N., M.S.N., CancerCare Manitoba, Winnipeg; Alexander Paterson, M.D., Department of Oncology, University of Calgary, Calgary, Alta.; Kathleen I. Pritchard, M.D., Department of Medicine, and Andrew Arnold, M.B., B.S., Department of Oncology, Mount Sinai Hospital, University of Toronto, Toronto; Richard Doll, M.S.W., Department of Patient and Family Counseling, and Susan E. O'Reilly, M.D., Department of Oncology, British Columbia Cancer Agency, Vancouver; and Gail Quirt, R.N., B.A.A., and Nicky Hood, R.N., Mount Sinai Hospital, University of Toronto, Toronto — all in Canada.

Address reprint requests to Dr. Goodwin at Mount Sinai Hospital, 1284-600 University Ave., Toronto, ON M5G 1X5, Canada, or at pgoodwin{at}mtsinai.on.ca.

Full Text of this Article


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.